CJC-1295 w/ dac 2mg

CJC-1295 with DAC 2 mg – Product Description

Overview:
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH). It is designed for extended activity in the body, allowing sustained stimulation of natural growth hormone (GH) release. It is typically supplied as a 2 mg lyophilized (freeze-dried) powder vial for research purposes.

Key Features:

• Active Compound: CJC-1295 with DAC
• Dosage/Form: 2 mg per vial
• Formulation: Lyophilized powder (white/off-white)
• Class: Long-acting GHRH analog peptide
• Half-life: Extended (several days due to DAC binding)
• Category: Research peptide (not an approved medication)

Mechanism of Action (Research Context):

CJC-1295 with DAC binds to GHRH receptors in the pituitary gland and:

• Stimulates natural growth hormone (GH) secretion
• Increases IGF-1 (Insulin-like Growth Factor-1) levels
• Extends GH release over a prolonged period due to DAC (which binds to albumin in the bloodstream)

This results in more stable and sustained GH signaling compared to short-acting peptides.

Common Research Applications:

• Growth hormone and endocrine system studies
• Metabolism and fat regulation research
• Muscle growth and recovery models
• Anti-aging and longevity-related research

Physical & Handling Information:

• Appearance: White/off-white powder in sealed vial
• Reconstitution: Requires sterile/bacteriostatic water (lab use only)
• Storage:
  • Unmixed: Store frozen (−20 °C recommended)
  • After reconstitution: Refrigerate at 2–8 °C

CJC-1295 with DAC vs Without DAC:

• With DAC:
  • Long-acting (days)
  • Less frequent dosing in research models
• Without DAC (Mod GRF 1-29):
  • Short-acting (minutes to hours)
  • Requires more frequent administration

Potential Risks & Side Effects (Non-clinical / Reported):

• Hormonal imbalance (excess GH/IGF-1)
• Water retention
• Joint pain or stiffness
• Headaches or flushing
• Possible insulin sensitivity changes

Warnings:

• Not approved for human or veterinary use
• Intended strictly for research/laboratory purposes
• Long-term safety in humans is not established
• Use outside controlled settings may pose serious health risks

Legal Status:

CJC-1295 with DAC is generally classified as a research chemical and is not approved as a prescription medication in most countries.

Important Note:

This product description is for informational and educational purposes only. CJC-1295 with DAC is an experimental peptide, and any non-research use carries significant health and legal risks. Always consult a qualified healthcare professional before considering any hormone-related substances.